Introduction {#S1}
============

Antibiotics play pivotal roles in disease prevention, growth promotion, and production improvement in animal husbandry ([@B16]; [@B8]; [@B54]). Nevertheless, the long-term use of antibiotics in animal breeding can accelerate the emergence of antibiotic-resistant bacteria (ARB), including *Staphylococcus aureus*, which can cause trauma infection, abscess, cellulitis, mastitis, endometritis, arthritis, septicemia, and sepsis in animals ([@B19]; [@B21]; [@B14]). It has been found that *S. aureus* is resistant to tetracycline, methicillin, erythromycin, clindamycin, ciprofloxacin, and vancomycin ([@B23]; [@B30]; [@B48]). The interactions among animals, humans, and the environment have also strengthened the spreading of ARB ([@B9]; [@B33]; [@B40]). These factors not only affect the effectiveness of prevention and treatment of animal diseases but also may endanger public safety ([@B12], [@B11]). Therefore, alternatives to antibiotics have become the spotlights of research in recent years ([@B31]; [@B43]).

Antimicrobial peptides (AMPs) are currently under evaluation as an alternative to antibiotics ([@B58]; [@B13]; [@B26]). AMPs have been identified in a variety of organisms ([@B67]; [@B5]), including insects, the largest population of living organisms on earth, which have great potential as a source of AMPs ([@B64]; [@B27]). Within insects, such a class of disulfide-rich peptides is referred to as "insect defensins" most of them consisted of about 40 amino acid (AA) residues, with an N-terminal loop, an α-helix, and an anti-parallel β-sheet cross-linked by three disulfide bonds (CSαβ) ([@B10]; [@B32]) and they have broad-spectrum activity against various Gram-positive bacteria, including methicillin-resistant *S. aureus* (MRSA) ([@B25]). However, most of these peptides have modest antibacterial activity and cytotoxicity, which limit their active implementation in medicine ([@B4]). Based on the key CSαβ scaffold, a few defensins such as tenecin 1, Def-AcAA, and plectasin have been designed with an improved activity and reduced cytotoxicity ([@B1]; [@B32]; [@B68]). Although both academia and start-ups are continuing their efforts, there are still few AMP-based antibiotics in use ([@B49]).

In our previous study, an insect defensin, DLP4, isolated from the hemolymph of *Hermetia illucens* larvae ([@B47]) showed a sequence identity ranging from 46.5 to 72.5% with the homologous sequences in the NCBI database. It displayed antibacterial activity against *S. aureus* and proved to be failed to induce resistance ([@B37]). However, the low antibacterial activity (16∼64 μg/mL) and relatively high cytotoxicity of DLP4 limit its effective application. In the study, to improve the antibacterial activity and reduce cytotoxicity of DLP4, a series of derivatives were generated by means of AA mutations in the native sequence ([@B15]). In addition, bioavailability, antimicrobial mechanism, and pharmacodynamics were studied *in vitro* and in a mouse thigh model infected with *S. aureus*.

Materials and Methods {#S2}
=====================

Bacterial Strains and Cell Lines {#S2.SS1}
--------------------------------

The bacterial strains *S. aureus* ATCC 43300, *Staphylococcus epidermidis* ATCC 12228, and *Escherichia coli* ATCC 25922 were purchased from American Type Culture Collection (ATCC). *S. aureus* CVCC 546, *Streptococcus pneumoniae* CVCC 2350, *Streptococcus suis* CVCC 3928, *Salmonella pullorum* CVCC 533, *Salmonella enteritidis* CVCC 3377, and *E. coli* K88 were purchased from the China Veterinary Culture Collection Center (CVCC). RAW 264.7 murine macrophages were obtained from Peking Union Medical College.

Reagents {#S2.SS2}
--------

Mueller--Hinton broth (MHB) and Mueller--Hinton agar (MHA) were obtained from BEIJING AOBOXING BIO-TECH CO., LTD (China). Sodium dodecyl sulfate (SDS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), trifluoroethanol (TFE), and propidium iodide (PI) were purchased from Sigma-Aldrich (China). Dulbecco's modified Eagle medium (DMEM) and fetal bovine serum (FBS) were obtained from Gibco (China).

Peptide Design, Expression, and Purification {#S2.SS3}
--------------------------------------------

To develop derivatives of peptide DLP4 with improved efficacy and to study the structure--activity relationship of DLP4, we analyzed sequences containing only six conserved cysteine residues in mature defensins retrieved from Antimicrobial Peptide Database (APD)^[1](#footnote1){ref-type="fn"}^ and used MUSCLE 3.8 for multiple sequence alignment ([Figure 1](#F1){ref-type="fig"}). Then, a series of derivatives were generated by AA substitution based on the template of parent peptide DLP4.

![**(A)** Representation of the 3D structure of DLP4 was built from Def-AcAA (PDB: 2nz3). Yellow, red, and green represent cysteines and disulfide bonds and charged and neutrally charged residues, respectively. **(B)** Multiple alignments of the insect defensins derived from APD were carried out using MUSCLE 3.8. The boxes above the alignment represent loop, helix, turns, and β strands, respectively. The black lines indicate the disulfide bond between cysteines. The "\*" under the sequences indicates positions which have a single, fully conserved residue, the ":" indicates conservation between groups of strongly similar properties, and the "." indicates conservation between groups of weakly similar properties. **(C)** Time curves of the total protein levels and cell wet weights. Total protein and biomass are measured every 24 h. Statistical significance of differences between 24 to 120 h and 0 h was determined using the two-way ANOVA and Dunnett's multiple comparisons. \*\*\**p* \< 0.001; \*\*\*\**p* \< 0.0001. **(D)** Tricine-SDS-PAGE and MALDI-TOF MS analysis of the purified ID13. M: ultra-low molecular weight protein marker; lane 1: purified ID13.](fmicb-11-01057-g001){#F1}

Recombinant plasmids were constructed by cloning the DLP4 and its analogs encoding sequence into the pPICZαA vector and transformed into *Pichia pastoris* X-33 for expression. Peptide purification was carried out with the AKTAxpress system. The purified peptides were characterized by tricine-sodium dodecyl sulfate polyacrylamide gel electrophoresis (Tricine-SDS-PAGE) and matrix-assisted laser desorption/ionization time-of-flight/time-of-flight tandem mass spectrometer (MALDI-TOF/TOF MS) (Ultraflextreme, Bruker, Germany) ([@B69]).

Structure Determination of Peptides {#S2.SS4}
-----------------------------------

### Determination of Disulfide Bonds {#S2.SS4.SSS1}

The S--S bonds in peptides were characterized through thermolysin enzymolysis followed by MALDI-TOF/TOF MS characterization ([@B34]). Simply, peptides were digested with thermolysin (Promega, United States) at the peptide/thermolysin ratio of 10:1 (w/w) in 100 mM ammonium acetate, 2 mM CaCl~2~ (pH 6.2) at 60°C for 1 h, after which the hydrolysates were separated by RP-HPLC, and characterized by MALDI-TOF/TOF MS (Ultraflextreme, Bruker, Germany).

### Circular Dichroism (CD) of Peptides {#S2.SS4.SSS2}

The secondary structure of AMPs can be determined by CD on a Bio-Logic MOS-450 spectropolarimeter (France). CD measurements of peptides were performed in ddH~2~O, 40 mM SDS, or 50% TFE using a 1.0-mm path-length cuvette; the spectra were recorded from 180 to 260 nm at room temperature three times ([@B38]).

Bioavailability Analyses {#S2.SS5}
------------------------

### Antimicrobial Activity {#S2.SS5.SSS1}

The minimal inhibitory concentration (MIC) was evaluated by a microtiter plate assay ([@B60]). Serial 2-fold dilutions of test peptides were placed into a 96-well plate containing identical bacterial inoculum and incubated at 37°C for 16∼20 h. Vancomycin was used as antibiotic control. The MIC value was defined as the lowest peptide concentration where no visible growth occurred. All tests were made in triplicate.

### Hemolysis {#S2.SS5.SSS2}

Hemolytic activity of peptides was evaluated with fresh mouse erythrocytes. Briefly, fresh mouse erythrocytes were collected, washed, and resuspended to a concentration of 8% (v/v) in PBS. Then, an aliquot of erythrocyte solution was added to 96-well plates containing an equal volume of peptide solution (1∼256 μg/mL) and was incubated for 1 h at 37°C. The erythrocyte suspension treated with 0.1% Triton X-100 and left untreated was employed as positive and negative controls, respectively. After centrifugation at 2000 rpm for 5 min, the supernatant was measured using a microplate reader at 576 nm. The percent hemolysis was calculated using the following formula: *Percenthemolysis* = \[(*A* − *A*~0~)/(*A*~100~ − *A*~0~)\] × 100%, where *A*, *A*~100~, and *A*~0~ represent the absorbance of the peptide sample and positive and negative controls, respectively.

### Mammalian Cytotoxicity {#S2.SS5.SSS3}

The cytotoxicity of peptides toward mouse macrophage RAW 264.7 was evaluated by the MTT assay as described previously ([@B57]).

Antimicrobial Mechanism of Peptides {#S2.SS6}
-----------------------------------

### Effects of Peptides on *S. aureus* Membrane {#S2.SS6.SSS1}

#### Membrane permeabilization {#S2.SS6.SSS1.Px1}

The effects of peptides on membrane permeabilization were measured by flow cytometry ([@B71]). Briefly, *S. aureus* CVCC 546 cells in the exponential phase (10^8^ CFU/mL, CFU: colony-forming units) were treated with peptides at 1×, 2×, or 4 × MIC and incubated with 50 μL PI at 0.5 mg/mL for 30 min at 25°C. Cells untreated and treated with 2 × MIC DLP4 or vancomycin were used as blank and positive controls. The fluorescence of the dye was monitored at an excitation wavelength of 488 nm and an emission wavelength of 635 nm.

#### Potassium ion (K^+^) leakage {#S2.SS6.SSS1.Px2}

To further investigate the effects of peptides on membrane integrity, K^+^ leakage determination was carried out as previously described ([@B42]). Briefly, *S. aureus* CVCC 546 cells were centrifuged, washed, and resuspended in 0.9% sterile saline. The cell suspension (10^8^ CFU/mL) was treated with peptides at 1 × MIC. Cells untreated and treated with DLP4 or nisin were used as blank and positive controls. At time intervals of 30, 60, 90, 120, and 150 min, the suspensions were centrifuged at 12000 rpm for 5 min. The supernatants were then subjected to measurement by Agilent inductively coupled plasma optical emission (ICP-OES).

### Effects of Peptides on *S. aureus* Genomic DNA {#S2.SS6.SSS2}

#### Gel retardation {#S2.SS6.SSS2.Px1}

A gel retardation assay ([@B70]) was utilized to analyze the binding of peptides to genomic DNA (gDNA) extracted from *S. aureus* CVCC 546 with TIANamp Bacteria DNA Kit (TIANGEN Biotech Co., Ltd., Beijing). The peptides were incubated for 10 min with gDNA at different ratios of 0--5.0 (w/w) and then loaded on 1% agarose gel for electrophoresis analysis.

#### Atomic force microscopy (AFM) {#S2.SS6.SSS2.Px2}

Atomic force microscopy images of gDNA-peptide complexes were carried out as described previously ([@B20]). Simply, gDNA (1 μg/mL) was incubated with equal-volume peptides (5 μg/mL) at 30°C for 10 min. Then, the sample was scanned by multimode 8 AFM (Bruker, United States).

#### CD spectra {#S2.SS6.SSS2.Px3}

Circular dichroism measurements ([@B3]) were carried out to examine the effect of peptide on the secondary structure of *S. aureus* CVCC 546 gDNA at peptide/gDNA ratios of 0.5 and 1, respectively. After incubation, the mixtures were loaded and scanned from 220 to 320 nm at room temperature with a Bio-Logic MOS450 spectropolarimeter (France).

Morphological Observations {#S2.SS7}
--------------------------

To further characterize the bactericidal effects of peptides, scanning electron microscopy (SEM) and transmission electron microscopy (TEM) were used to visualize the morphological changes. *S. aureus* CVCC 546 cells in the exponential phase (10^8^ CFU/mL) were treated with 4 × MIC peptides at 37°C for 2 h or left untreated as control. Cells for SEM or TEM were processed as described previously ([@B61]) and samples were observed using a QUANTA 200 SEM (FEI, Philips, Netherlands) or a JEM-1400 (JEDL, Tokyo, Japan).

*In vitro* and *in vivo* Pharmacodynamics {#S2.SS8}
-----------------------------------------

### Time-Kill Assay {#S2.SS8.SSS1}

Time-kill assay was used to assess the killing rates of *S. aureus* cells by AMPs *in vitro*, done by measuring the number of viable bacteria left at various times after exposure to the peptides. Simply, reagents were added to MHB medium containing 10^5^ CFU/mL *S. aureus* CVCC 546 at the final concentrations of 1×, 2×, or 4 × MIC; the mixture was incubated at 37°C and 250 rpm. At different time intervals, a certain sample was taken, serially diluted, and plated on MHA for colonies counting. Cells treated with 2 × MIC DLP4 or vancomycin and left without treatment were used as the positive and blank controls, respectively ([@B18]).

### Post-antibiotic Effect (PAE) {#S2.SS8.SSS2}

The PAE was determined by exposing *S. aureus* cells to antimicrobial agent at 1×, 2×, or 4 × MIC for 2 h. After drug removal by dilution, the bacterial culture was incubated at 37°C and 250 rpm. An aliquot of samples (50 μL) were taken for CFU counts at different time intervals until bacterial cultures became turbid. Bacteria treated with DLP4 or vancomycin and left without treatment were used as the positive and blank controls, respectively. The PAE was calculated using the following formula: *PAE* = *T* − *C*, where *T* is the time for the CFU counts to increase by 10-fold above the count observed immediately after drug removal, and *C* is the corresponding time for the untreated control ([@B46]).

### Mouse Thigh Infection Model {#S2.SS8.SSS3}

Mouse experiments were carried out at Gene Engineering Laboratory, Feed Research Institute of Chinese Academy of Agricultural Sciences (CAAS) and complied with institutional animal care and use policies and procedures (AEC-CAAS-20090609). All animal studies were performed with female CD-1 mice, 6∼7 weeks old.

*S. aureus* CVCC 546 in the exponential phase were resuspended in MHB and adjusted to 1 × 10^8^ CFU/mL, a 0.1-mL inoculum was injected into the right thighs of mice. At 2 h post-infection, mice (*n* = 6) were administered intraperitoneally (i.p.) with peptides at 2.5, 5, or 10 mg/kg. Mice raised without any treatment, or treated with PBS, 10 mg/kg DLP4, or vancomycin were used as the blank and negative and positive controls, respectively. At 24 h post-infection, peripheral blood was collected and serum was separated for cytokine levels analysis by using enzyme-linked immunosorbent assay (ELISA) kit (R&D systems, United States). Mice were euthanized, the right thighs were aseptically removed and processed for colonies counting ([@B39]).

Statistical Analysis {#S2.SS9}
--------------------

All data are presented as mean ± standard deviation (SD), where "*n*" represents the number of animals or samples. Statistical analysis was performed by one-way or two-way analysis of variance (ANOVA) followed by Dunnett's multiple comparisons test using GraphPad Prism 7 or OriginPro 8. *p* \< 0.05 was considered statistically significant.

Results {#S3}
=======

Peptide Design and Expression {#S3.SS1}
-----------------------------

As shown in [Figures 1A,B](#F1){ref-type="fig"}, a multiple alignment revealed insect defensins retrieved from APD share high homology of 59%∼87.5% between the primary structures of those peptides, which comprise three apparent regions, an N-terminal loop, a central amphipathic α helix, and a C-terminal anti-parallel β-sheet. The helix is separated from the β-sheet by turn T1 and the two β-sheets by turn T2. In addition to the similar structural topology, the specifics of different insect defensins are diverse. The loop motif shows high variability, especially for DLP4, where the terminal of the loop account for its particular variability. The helix always ends with the R23 residue, followed by a G residue which is involved in a hydrogen bond with the carbonyl group of C3 ([@B32]). Hydrophobic side chains distributed over the surface present a number of hydrophobic spots, some of which correspond to conservative AA: A1, T2, L5, L6, A15, and A17; others are more specific: P8, A14, and W29 for DLP4, I9, L18, L21, and F22 for Sapecin C; and I11 for Phormicin A. Charged residues at the end of the helix, turns T1 and T2, and the C-terminus form positive areas. Variable and conserved regions were also displayed ([Figure 1B](#F1){ref-type="fig"}), based on these regions, peptides ID1∼ID3 were designed by substituting cysteines in one pair of disulfide bonds with A residue; ID4∼ID7 were changed at the conservative sites with AA of similar properties; ID8∼ID26 were generated with varied charges through a basic or acidic AA replacement; ID27∼ID30 were designed by changing hydrophobicity while keeping charge unchanged ([Table 1](#T1){ref-type="table"} and [Supplementary Table S1](#DS1){ref-type="supplementary-material"}).

###### 

Physicochemical parameters of parental and designed peptides.

  Peptide   Sequences                                                                   MW^a^     Net charge   Hydrophobicity   A1^b^   A2^c^
  --------- --------------------------------------------------------------------------- --------- ------------ ---------------- ------- -------
  DLP4      ATCDLLSPFKVGHAACAAHCIARGKRGGWCDKRAVCNCRK                                    4269.05   6            0.354            16      16
  ID1       AT**[A]{.ul}**DLLSPFKVGHAACAAHCIARGKRGGW**[A]{.ul}**DKRAVCNCRK              4206.93   6            0.292            --      --
  ID2       ATCDLLSPFKVGHAA**[A]{.ul}**AAHCIARGKRGGWCDKRAV**[A]{.ul}**NCRK              4206.93   6            0.292            --      --
  ID3       ATCDLLSPFKVGHAACAAH**[A]{.ul}**IARGKRGGWCDKRAVCN**[A]{.ul}**RK              4206.93   6            0.292            --      --
  ID4       ATCD**[I]{.ul}**LSPFKVGHAACAAHCIARGKRGGWCDKRAVCNCRK                         4269.05   6            0.356            32      ND
  ID5       ATCDL**[I]{.ul}**SPFKVGHAACAAHCIARGKRGGWCDKRAVCNCRK                         4269.05   6            0.356            16      ND
  ID6       ATCDLL**[T]{.ul}**PFKVGHAACAAHCIARGKRGGWCDKRAVCNCRK                         4283.08   6            0.361            8       16
  ID7       ATCDLLSPFKVGHAACAAHCIARGKR**[S]{.ul}**GWCDKRAVCNCRK                         4299.08   6            0.353            --      --
  ID8       ATCDLLS**[K]{.ul}**FKVGHAACAAHCIARGKRGGWCDKRAVCNCRK                         4300.11   7            0.311            32      ND
  ID9       ATCDLLSPFKV**[K]{.ul}**HAACAAHCIARGKRGGWCDKRAVCNCRK                         4340.17   7            0.329            16      ND
  ID10      ATCDLLSPFKVGHAACAAHCIARGKRGGWC**[N]{.ul}**KRAVCNCRK                         4268.07   7            0.358            16      ND
  ID11      ATCDLLSPF**[G]{.ul}**VGHAACAAHCIARGKRGGWCDKRAVCNCRK                         4197.93   5            0.379            16      ND
  ID12      ATCDLLSPFKVGHAACAAHCIARG**[N]{.ul}**RGGWCDKRAVCNCRK                         4254.98   5            0.364            --      --
  ID13      ATCDLLSPFKVGHAACAAHCIARGKRGGWCD**[G]{.ul}**RAVCNCRK                         4197.93   5            0.379            4       4
  ID14      ATCDLLSPFKVGHAACAAHCIARGKRGGWCDKRAVCNCR**[N]{.ul}**                         4254.98   5            0.364            --      --
  ID15      ATCDLLSPF**[G]{.ul}**VGHAACAAHCIARG**[N]{.ul}**RGGWCDKRAVCNCRK              4183.86   4            0.388            --      --
  ID16      ATCDLLSPF**[G]{.ul}**VGHAACAAHCIARGKRGGWCD**[G]{.ul}**RAVCNCRK              4126.81   4            0.403            8       16
  ID17      ATCDLLSPF**[G]{.ul}**VGHAACAAHCIARGKRGGWCDKRAVCNCR**[N]{.ul}**              4183.86   4            0.388            16      64
  ID18      ATCDLLSPFKVGHAACAAHCIARG**[N]{.ul}**RGGWCD**[G]{.ul}**RAVCNCRK              4183.86   4            0.388            16      ND
  ID19      ATCDLLSPFKVGHAACAAHCIARG**[N]{.ul}**RGGWCDKRAVCNCR**[N]{.ul}**              4240.91   4            0.373            --      --
  ID20      ATCDLLSPFKVGHAACAAHCIARGKRGGWCD**[G]{.ul}**RAVCNCR**[N]{.ul}**              4183.86   4            0.388            16      ND
  ID21      ATCDLLSPF**[G]{.ul}**VGHAACAAHCIARG**[N]{.ul}**RGGWCD**[G]{.ul}**RAVCNCRK   4112.74   3            0.413            --      --
  ID22      ATCDLLSPFKVGHAACAAHCIARG**[N]{.ul}**RGGWCD**[G]{.ul}**RAVCNCR**[N]{.ul}**   4169.79   3            0.398            --      --
  ID23      ATCDLLSPFKVGHAACAAHCIARGKRGGWCD**[D]{.ul}**RAVCNCR**[N]{.ul}**              4241.89   3            0.369            --      --
  ID24      ATCDLLS**[K]{.ul}**FKV**[K]{.ul}**HAACAAHCIARGKRGGWCDKRAVCNCRK              4371.23   8            0.286            --      --
  ID25      ATCDLLSPFKV**[K]{.ul}**HAACAAHCIARGKRGGWC**[N]{.ul}**KRAVCNCRK              4339.19   8            0.333            --      --
  ID26      ATCDLLS**[K]{.ul}**FKVGHAACAAHCIARGKRGGWC**[N]{.ul}**KRAVCNCRK              4299.12   8            0.315            --      --
  ID27      ATCDLLSPFKVGHAACA**[L]{.ul}**HCIARGKRGGWCDKRAVCNCRK                         4311.13   6            0.388            8       8
  ID28      ATCDLLSPFKVGHAACA**[V]{.ul}**HCIARGKRGGWCDKRAVCNCRK                         4297.1    6            0.377            8       16
  ID29      ATCDLLSPFKVGHAACAAHC**[L]{.ul}**ARGKRGGWCDKRAVCNCRK                         4269.05   6            0.351            64      128
  ID30      ATCDLLSPFKVGHAACAAHCIARGKRGGWCDKRA**[I]{.ul}**CNCRK                         4283.08   6            0.368            16      32

Changed amino acids are shown in bold and underlined.

a

Molecular weight (Da).

b

Activities (MICs, μg/mL) of peptides were tested against S. aureus ATCC 43300; inactive peptides are indicated by "--," tested by drop-diffusion assay.

c

Activities (MICs, μg/mL) of peptides were tested against S. aureus CVCC 546; inactive peptides are indicated by "--," tested by drop-diffusion assay; ND: not determined.

The peptides listed in [Table 1](#T1){ref-type="table"} were inserted into plasmids and successfully expressed in *P. pastoris* X-33. The production of peptide ID13 was performed in a 5-L fermenter with total protein of 761 mg/L and biomass of 385 g/L at 120 h by induction ([Figure 1C](#F1){ref-type="fig"}). A molecular weight of 4197.01 Da was shown by MALDI-TOF/TOF MS ([Figure 1D](#F1){ref-type="fig"}), which was consistent with the theoretical molecular mass of 4197.93 Da of ID13 ([Table 1](#T1){ref-type="table"}).

Bioavailability of ID13 {#S3.SS2}
-----------------------

### Antibacterial Activity {#S3.SS2.SSS1}

The MICs of DLP4 and its analogs were tested preferentially against *S. aureus* ATCC 43300, among them, peptide ID13 (with the MIC of 4 μg/mL) exerted the most potent antibacterial activity against *S. aureus* ATCC 43300, and the MICs of other 29 derivatives were 8∼64 μg/mL ([Table 1](#T1){ref-type="table"}). The MICs of peptide ID13 were further tested against other Gram-positive bacteria and Gram-negative bacteria. The result showed that ID13 (with MICs of 4∼8 μg/mL) had higher activity than DLP4 (with MICs of 16∼64 μg/mL) against *S. aureus* CVCC 546, *S. epidermidis* ATCC 12228, *S. pneumoniae* CVCC 2350, and *S. suis* CVCC 3928 ([Table 2](#T2){ref-type="table"}). However, similar to DLP4, ID13 had no activity against Gram-negative bacteria.

###### 

MICs of the designed peptides against pathogenic strains.

  Species and strains                    MICs                                        
  -------------------------------------- --------- ------- --------- ------- ------- ------
  **Gram-positive bacteria**                                                         
  *Staphylococcus aureus* CVCC 546       0.95      4       3.75      16      0.67    1
  *S. epidermidis* ATCC 12228            1.91      8       14.99     64      0.67    1
  *Streptococcus pneumoniae* CVCC 2350   0.95      4       7.50      32      0.34    0.5
  *S. suis* CVCC 3928                    0.95      4       3.75      16      0.17    0.25
  **Gram-negative bacteria**                                                         
  *Escherichia coli* ATCC 25922          \>30.50   \>128   \>29.98   \>128   86.15   128
  *E. coli* K88                          \>30.50   \>128   \>29.98   \>128   43.08   64
  *Salmonella pullorum* CVCC 533         \>30.50   \>128   \>29.98   \>128   86.15   128
  *S. enteritidis* CVCC 3377             \>30.50   \>128   \>29.98   \>128   86.15   128

### Hemolysis and Cytotoxicity of Peptide ID13 {#S3.SS2.SSS2}

As shown in [Figure 2](#F2){ref-type="fig"}, the hemolysis of ID13 against mouse erythrocytes was 0.38% at 128 μg/mL, lower than that of DLP4 (0.61%) and vancomycin (0.54%). The cell viability of ID13 against mouse macrophages RAW 264.7 was 71.4% at 256 μg/mL, higher than that of DLP4 (63.8%), but lower than that of vancomycin (85.8%). The results indicated that ID13 had lower hemolysis and cytotoxicity than DLP4.

![**(A)** Hemolytic activities of ID13, DLP4, and vancomycin (Van) against mouse erythrocytes (*n* = 3). **(B)** Cytotoxicity of ID13, DLP4, and vancomycin (Van) against RAW 264.7 (*n* = 4). Mean values in the same concentration with different lowercase letters indicate a significant difference (*p* \< 0.05).](fmicb-11-01057-g002){#F2}

Structure Determination of Peptide ID13 {#S3.SS3}
---------------------------------------

### Disulfide Bonds of Peptide ID13 {#S3.SS3.SSS1}

To locate the disulfide bonds in ID13, the cysteine-containing peptide pairs were obtained by thermolytic digestion, and characterized by MALDI-TOF/TOF MS. As shown in [Supplementary Figure S1](#DS1){ref-type="supplementary-material"}, the disulfide bond--unreduced peptide fragments ATCDLLSPFK and GGWCDGR showed a m/z of 921.4, suggesting they were connected by Cys3 and Cys30, and VGHAACAAHCIAR and AVCNCR had a m/z of 970.45, indicating they were cross-linked by Cys13 and Cys23, and Cys20 and Cys38. The results agreed with those predicted from the Def-AcAA ([Figure 1A](#F1){ref-type="fig"}).

### CD of Peptide ID13 {#S3.SS3.SSS2}

The secondary structure of the peptide was measured in the presence of H~2~O, 50% TFE, or 40 mM SDS which were used to simulate aqueous, microbial membrane and hydrophobic conditions, respectively ([@B51]). CD spectra showed peptide ID13 ([Figure 3A](#F3){ref-type="fig"}) as well as DLP4 ([Figure 3B](#F3){ref-type="fig"}) possessed a positive peak between 185 and 195 nm followed by two negative peaks at approximately 208 and 222 nm, indicating an αβ structure in all three environments. Compared with DLP4, the CD peaks of ID13 decreased in H~2~O and 50% TFE and increased in 40 mM SDS. It suggested that ID13 tended to form α-helix in microbial membrane (40 mM SDS) conditions while DLP4 was prone to form α-helix in hydrophobic conditions (50% TFE).

![CD spectra of the peptide ID13 **(A)** and DLP4 **(B)** in H~2~O, 40 mM SDS, or 50% TFE.](fmicb-11-01057-g003){#F3}

Anti-*S. aureus* Mechanism of Peptide ID13 {#S3.SS4}
------------------------------------------

### Effects of ID13 on *S. aureus* Membrane {#S3.SS4.SSS1}

#### Membrane permeabilization {#S3.SS4.SSS1.Px1}

Propidium iodide can penetrate the damaged cell membrane and intercalate into DNA and was utilized to assess the membrane integrity of *S. aureus* CVCC 546 cells. As shown in [Figure 4A](#F4){ref-type="fig"}, in the absence of peptides, 1.18% of the cells showed PI fluorescent signal. When treated with ID13 at 1×, 2×, or 4 × MIC for 0.5 h, the percentage of PI-positive cells were 47.2%, 48.2%, and 52.8%, respectively. By comparison, after being treated with 2 × MIC DLP4 or vancomycin, the percentages of PI-positive cells were 41.8% and 5.1%, respectively. It indicated that ID13 induced more potent damage to *S. aureus* CVCC 546 than its parent peptide DLP4, and the action mode of ID13 and DLP4 may be different from that of vancomycin.

![**(A)** Flow cytometric analysis of *S. aureus* CVCC 546. Cells were treated with 1×, 2×, or 4 × MIC ID13, respectively; cells treated with 2 × MIC DLP4 or vancomycin (Van) and left without treatment were used as the positive and negative control, respectively (*n* = 3). **(B)** The extracellular levels of K^+^ released by *S. aureus* CVCC 546 cells treated with peptide ID13, DLP4, and nisin, respectively (*n* = 3). Statistical significance of differences was determined using **(A)** one-way and **(B)** two-way ANOVA followed by Dunnett's multiple comparison. \*\*\*\**p* \< 0.0001.](fmicb-11-01057-g004){#F4}

#### K^+^ leakage {#S3.SS4.SSS1.Px2}

To further demonstrate the impacts of peptide ID13 on the cell membrane integrity of *S. aureus* CVCC 546 cells, the levels of K^+^ released from *S. aureus* CVCC 546 cells were determined by ICP-MS. As shown in [Figure 4B](#F4){ref-type="fig"}, in the absence of peptide ID13, the amount of extracellular K^+^ was relatively stable at low level of 0.31∼0.56 mg/L. By comparison, after being treated for 150 min, the levels of released K^+^ from *S. aureus* CVCC 546 were up to 0.81 mg/L by ID13, 0.72 mg/L by DLP4, and 1.03 mg/L by nisin. The results suggested that the destruction of the cell membrane by ID13 is more potent than DLP4, which was consistent with the results of PI-positive cells.

### Effects of ID13 on *S. aureus* Genomic DNA {#S3.SS4.SSS2}

#### DNA binding {#S3.SS4.SSS2.Px1}

To probe potential intracellular targets, the DNA gel retardation assay and AFM were performed. As shown in [Figure 5A](#F5){ref-type="fig"}, ID13 began to retard the migration of *S. aureus* CVCC 546 gDNA at the peptide/gDNA mass ratio of 1 while DLP4 did at 0.5. The DNA-binding ability was enhanced with the increase in peptide/gDNA mass ratio. gDNA was completely blocked at ID13/gDNA of 5 and that for DLP4/gDNA at 2.5. Furthermore, the AFM images also showed that DLP4 had a stronger binding ability to gDNA than that of ID13 ([Figure 5B](#F5){ref-type="fig"}), which may ascribe to its more net positive charges ([Table 1](#T1){ref-type="table"}).

![The binding of ID13 and DLP4 to *S. aureus* CVCC 546 gDNA. **(A)** Gel retardation analysis of the binding of ID13 and DLP4 to *S. aureus* CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, 1, 2.5, and 5, respectively. M: λDNA/Hind III marker. **(B)** Atomic force microscopy (AFM) analysis of the binding of ID13 and DLP4 to *S. aureus* CVCC 546 gDNA. **(C)** CD spectra of *S. aureus* CVCC 546 gDNA at peptide/gDNA mass ratios of 0, 0.5, and 1, respectively.](fmicb-11-01057-g005){#F5}

#### CD spectra {#S3.SS4.SSS2.Px2}

Circular dichroism was utilized to estimate the conformation changes of bacterial gDNA caused by ID13. Native bacterial gDNA presents a B conformation, which provides a conservative CD spectrum with a positive band around 270 nm and a negative one around 245 nm ([@B63]). When exposed to ID13, precipitation in gDNA was observed, the positive band at 270 nm decreased and the negative one at 245 nm gradually disappeared. In contrast, the CD band of DLP4-treated gDNA showed more intense changes ([Figure 5C](#F5){ref-type="fig"}), which may attribute to its increased charge. It indicated that ID13 as well DLP4 can interact with gDNA and destruct its structure.

Morphological Characterization {#S3.SS5}
------------------------------

The microscopic morphology and ultrastructure changes of *S. aureus* CVCC 546 were observed by SEM and TEM. As shown in [Figure 6A](#F6){ref-type="fig"}, compared with the intact control group, the cell surface of peptide ID13-treated *S. aureus* CVCC 546 was significantly changed, with evident cell envelope perforation and deformation. TEM image showed a complete microscopic surface and a dense internal structure of *S. aureus* CVCC 546 cells in the control. In contrast, ID13 significantly damaged *S. aureus* CVCC 546 ultrastructure, including the rupture of cell envelope, the release of intracellular contents, the formation of mesosome-like structure and empty regions, and complete lysis of the cells. Compared to ID13, it seemed DLP4 caused less damage to *S. aureus* CVCC 546 ([Figure 6B](#F6){ref-type="fig"}). Furthermore, there were no obvious morphological changes in the 4 × MIC vancomycin--treated *S. aureus* CVCC 546 cells ([Figure 6](#F6){ref-type="fig"}), indicating different action modes between peptides ID13, DLP4, and vancomycin.

![**(A)** SEM and **(B)** TEM micrographs of *S. aureus* CVCC 546 treated with ID13, DLP4, or vancomycin (Van) at 4 × MIC for 2 h or left untreated as control. Red arrow: membrane perforation; yellow arrow: cell shrinkage; green arrow: leakage of cytosol; blue arrow: empty regions; cyan arrow: mesosome-like structure; black arrow: cell rupture.](fmicb-11-01057-g006){#F6}

Pharmacodynamics of Peptide ID13 {#S3.SS6}
--------------------------------

Based on the attractive mode in which peptide ID13 acts, we investigated its potential as a therapeutic drug through time-kill assay, PAE, and mouse thigh infection model.

### Time-Kill Assay {#S3.SS6.SSS1}

As shown in [Figure 7A](#F7){ref-type="fig"}, after being treated with 1×, 2×, or 4 × MIC ID13, the CFU counts of *S. aureus* CVCC 546 decreased within 1 h by 2.16, 3.14, and 3.4 log~10~ CFU/mL, respectively, equivalent to a CFU reduction of more than 99.99%. In contrast, for 2 × MIC DLP4 or vancomycin, there was a reduction of 2.7 log~10~ CFU/mL and 0.22 log~10~ CFU/mL, respectively. The results suggested that ID13 had more potent bactericidal activity against *S. aureus* CVCC 546 cells than did DLP4 and vancomycin. Furthermore, the regrowth of bacterial cells was observed after being treated with 2 × MIC vancomycin in the post-incubation time. Note that the common clinical failure of vancomycin in the treatment of *S. aureus* may relate to its the poor bactericidal activity ([@B50]; [@B28]).

![The efficacy of peptide ID13 *in vitro* and *in vivo* with DLP4 and vancomycin (Van) as positive controls. **(A)** Time-kill assay of ID13, DLP4, and vancomycin (Van) against *S. aureus* CVCC 546 (*n* = 3). **(B)** PAEs of ID13, DLP4, and vancomycin (Van) against *S. aureus* CVCC 546 (*n* = 3). **(C)** Single i.p. treatment with ID13, DLP4, and vancomycin (Van) in the mouse thigh infection model (*n* = 6). Effects of ID13, DLP4, and vancomycin (Van) on inflammatory cytokine levels of **(D)** TNF-α, **(E)** IL-6, and **(F)** IL-10. Statistical significance of differences was determined using the two-way ANOVA for **(A)** and one-way ANOVA for **(B--F)**, followed by Dunnett's multiple comparison. (\*) indicates the significance between ID13, DLP4, or vancomycin and PBS. \*\**p* \< 0.01; \*\*\**p* \< 0.001; \*\*\*\**p* \< 0.0001.](fmicb-11-01057-g007){#F7}

### PAE {#S3.SS6.SSS2}

Post-antibiotic effect is an important indicator of medication frequency ([@B66]). ID13 produced a longer PAE (12.78 ± 0.28 h) against *S. aureus* CVCC 546 than that of DLP4 (8.20 ± 0.19 h) and vancomycin (1.36 ± 0.20 h) at 2 × MIC. Increasing the concentrations of ID13 significantly prolonged its duration of PAE ([Figure 7B](#F7){ref-type="fig"}).

### Mouse Thigh Infection Model {#S3.SS6.SSS3}

The *in vivo* efficacy was then performed in a mouse thigh infection model. At 2 h post-infection with *S. aureus* CVCC 546, ID13 was administered i.p. at single doses ranging from 2.5 to 10 mg/kg. The result showed that ID13 generated a 1.8 log~10~ (CFU/g) reduction in infected thigh muscles at 10 mg/kg, superior to DLP4 with 1.7 log~10~ (CFU/g) and vancomycin with 0.77 log~10~ (CFU/g) ([Figure 7C](#F7){ref-type="fig"}). Moreover, it observed a significant downregulation of serum levels of TNF-α, IL-6, and IL-10 by 1123.30 pg/mL, 750.02 pg/mL, and 37.66 pg/mL, respectively, superior to DLP4 (TNF-α: 1103.30 pg/mL, IL-6: 710.02 pg/mL, and IL-10: 29.06 pg/mL) and vancomycin (TNF-α: 1052.98 pg/mL, IL-6: 497.48 pg/mL, and IL-10: 15.82 pg/mL) at the same concentration (10 mg/kg) ([Figures 7D--F](#F7){ref-type="fig"}).

Discussion {#S4}
==========

*Staphylococcus aureus* is disreputable for its potential to get resistance to antibiotics, attracting attention to novel antimicrobial strategies ([@B7]; [@B59]). The clinical development of AMPs is currently under evaluation. However, most of these AMPs have low antimicrobial activity and relatively high cytotoxicity ([@B17]; [@B29]; [@B4]), which limit their therapeutic application\[15\]. Insect defensins are a group of evolutionarily conserved AMPs with a length distribution between 32 and 52 residues and charges vary from −5 to +8. They share a common CSαβ motif, which have been proved to be valuable structural templates in peptide engineering ([@B27]). In this work, a naturally occurring sequence DLP4 was used as a template to design more potent and low toxic molecules.

In general, bioactivity of AMPs is strongly associated with their structures; especially the presence of intramolecular disulfide bonds is critical for their conformation and bioactivity ([@B27]). In our work, peptides ID1--ID3 (with one pair of disulfide bonds blocked by alanine) presented no activity in a drop-diffusion assay ([Table 1](#T1){ref-type="table"}). Similar results have also been reported for lucifensin and coprisin ([@B6]; [@B34]). Studies have shown that truncated defensins at the N-terminal caused decreased antimicrobial activity ([@B35]; [@B6]), yet fail to identify single residues that are responsible and highlighting the complexity of sequence-based approaches. In our study, single-conserved AA mutation L5I, L6I, and S7T (with ID4, ID5, and ID6, respectively) in the N-terminal loop had no significant effect on the antibacterial activity. However, the mutant ID7 (with G27S) showed no antibacterial activity, which may be due to the effect of hydroxyl groups of S residues on the anti-parallel sheet conformation ([@B41]). Additionally, the net positive charges play an important role in influencing the antibacterial activity of AMPs ([@B52]); however, the correlation between peptide charge and bioactivity is complex ([@B24]). In our study, it showed no linear relationship between the charge and activity of peptides ([Table 1](#T1){ref-type="table"}); however, it presented a threshold (+4∼+7), within which the engineered peptides (ID8∼ID26) showed antimicrobial activity. It has been reported that charged residues (K or R) located at the T1 (AA from 24 to 27) and T2 turns (AA 32 and 33) on the surface of the molecules are particularly important for the activity of insect defensins ([@B32]); however, in our study, the substitution of K32 in T2 turn with G (ID13) generated a more antimicrobial activity and less toxic molecule. Moreover, amphipathicity is another main parameter responsible for the activity of the engineered peptides ([@B65]; [@B24]). When replacing the hydrophobic AA (A6) of the α-helix wheel with the similar but more hydrophobic AA (L or V) which further improves hydrophobicity, the antimicrobial ability of the designed peptides increased compared to the native peptide. Likewise, the mutation I9L of the α-helix wheel with decreased hydrophobicity resulted in a declined antimicrobial ability ([Table 1](#T1){ref-type="table"} and [Supplementary Figure S2](#DS1){ref-type="supplementary-material"}). Studies showed that hydrophobic residues in the β-sheet replaced by A residue resulted in dramatically decreased biological function of the engineered peptides ([@B55]; [@B62]). However, in our study, when the hydrophobic V35 in the β-sheet was replaced by I residue, the activity of peptide ID30 was not affected. Altogether, the CSαβ scaffold is a prerequisite for the activity of the peptide, whereas the activity of the peptides has no linear relationship with charge but increases with the overall hydrophobicity.

The MIC value is a key factor in preliminary screening of candidate peptides, for which ≤16 μg/mL or ≤16 μmol/L has been posed as a requirement in clinical studies ([@B4]). In this study, compared with DLP4, ID13 had a lower MIC value (4∼8 μg/mL), hemolytic activity (0.38%), and cytotoxicity (71.4% viability) ([Table 2](#T2){ref-type="table"} and [Figure 2](#F2){ref-type="fig"}), which may be related to the different α-helix content between peptide ID13 and DLP4 in bacterial membrane mimicking (40 mM SDS) and neutral membrane conditions (50% TFE) ([Figure 3](#F3){ref-type="fig"}; [@B61]); the higher α-helix content of peptides indicates the stronger affinity of peptide to cell membranes and thus more potent activity and toxicity ([@B4]). An increase in total hydrophobicity in a certain range also increased the antibacterial activity of ID13 ([Table 1](#T1){ref-type="table"}). The cell envelope is regarded as the initial contact point of most natural AMPs. Then, AMPs can destroy the cell envelope and effectively induce a leakage of cytosol ([@B24]). It has been proven in our study that ID13 had the ability to destroy the cell envelope and cause K^+^ or other contents to release extracellularly ([Figures 4](#F4){ref-type="fig"}, [6](#F6){ref-type="fig"}), and then bound to intracellular target gDNA and destroyed its helical structure ([Figure 5](#F5){ref-type="fig"}), which might result in the inhibition of DNA synthesis ([@B22]). In contrast, DLP4 showed less potent damage to cell membrane than that of ID13 ([Figures 4](#F4){ref-type="fig"}, [6](#F6){ref-type="fig"}), but it showed stronger binding ability to *S. aureus* gDNA ([Figure 5](#F5){ref-type="fig"}), which might attribute to its less α-helix content in bacterial membrane mimicking conditions and more net positive charges. Other peptides also showed cell membrane damaging abilities to different bacteria ([@B45]; [@B36]). The action mode of ID13 and DLP4 is completely different from that of vancomycin which targets the D-Ala-D-Ala terminus of peptidoglycan to inhibit the cell wall biosynthesis ([@B56]).

Pharmacodynamics has been integral to the design of rational drug dosing regimens ([@B53]). Our findings showed that ID13 had excellent bactericidal efficiency, a long PAE, and high efficacy in a mouse thigh infection model against *S. aureus* CVCC 546 and was superior to DLP4 or vancomycin ([Figure 7](#F7){ref-type="fig"}). Compared with antibiotics, AMPs is less easily to cause bacterial resistance ([@B44]), and it is likely that any changes of bacteria to avoid the AMPs attack are also to grievously influence the proliferation of bacteria ([@B2]). All these mean a lower dose and less frequency in administration, thereby potentially reducing treatment costs, drug exposure, and drug resistance. Above all, ID13 presents excellent properties and potency for biomedical applications.

In conclusion, a naturally occurring sequence DLP4 was used as a starting template for rational design of a novel class of "CSαβ AMPs." Of these peptides, ID13 showed the best antibacterial activity and reduced cytotoxicity and could penetrate and destroy the cell membrane of *S. aureus* CVCC 546, resulting in an increase in K^+^ leakage. After being treated with ID13, perforated, wrinkled, and collapsed *S. aureus* cells were observed by SEM and TEM. Additionally, ID13 showed potent bactericidal efficiency, a prolonged PAE, and high efficacy in a mouse thigh infection model and was superior to DLP4 or vancomycin. These results suggest that ID13 may be a novel promising antimicrobial candidate to treat infectious diseases caused by *S. aureu*s.
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